Semaglutide

Semaglutide is a GLP-1 receptor agonist — a class of compound that mimics glucagon-like peptide-1, a hormone naturally produced by the intestine after eating. When GLP-1 binds to receptors in the brain, it signals satiety, slows gastric emptying, and reduces appetite. The result is a sustained reduction in caloric intake that doesn't rely solely on willpower or behavioral modification. Semaglutide is administered by subcutaneous injection, typically once weekly, with dosing titrated gradually to the therapeutic level under physician supervision. As with all treatments prescribed through OLIV Well, dosing and protocol are determined by your licensed telehealth provider based on your individual intake.

Semaglutide was originally developed for the management of type 2 diabetes and received its first FDA approval for that indication in 2017. Researchers subsequently observed significant weight reduction in patients using GLP-1 receptor agonists, which prompted dedicated clinical investigation into its use for weight management. Large-scale trials — including the STEP trial program — enrolled thousands of participants and demonstrated clinically meaningful reductions in body weight when semaglutide was combined with lifestyle intervention. These findings formed the basis for subsequent regulatory review and the expanding use of GLP-1 receptor agonists in weight management protocols. Compounded semaglutide prescribed through OLIV Well is not FDA-approved for a specific indication, but is produced at FDA-registered, 503A-compliant compounding pharmacies to pharmaceutical-grade standards.

As with any prescription compound, semaglutide may cause side effects. The most commonly reported include nausea (most common, typically mild and reduced over time with dose titration), vomiting, diarrhea or constipation, decreased appetite, fatigue, and injection site reactions. Less common but more serious effects can include changes in heart rate and, in rare cases, pancreatitis. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use semaglutide. This is not a complete list. Your OLIV Well provider will review your health history before prescribing and will discuss any contraindications specific to your situation.

Function: Semaglutide activates GLP-1 receptors in the hypothalamus and gastrointestinal tract, reducing appetite signaling and slowing gastric emptying. This creates a physiological environment where caloric restriction is more sustainable and less reliant on active behavioral effort alone. Benefit: For patients who have found weight management difficult despite diet and exercise, semaglutide offers a clinically supported pathway. It addresses the hormonal and physiological contributors to weight gain — not just the behavioral ones. The result, when properly dosed and supervised, is weight management support that works at the level of the body's own systems.